H2020-JTI-IMI-2016

IDENTIFICATION AND VALIDATION OF BIOMARKERS FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ACROSS THE SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

JOINT INFLUENZA VACCINE EFFECTIVENESS STUDIES

DATA QUALITY IN PRECLINICAL RESEARCH AND DEVELOPMENT

ADDRESSING THE CLINICAL BURDEN OF CLOSTRIDIUM DIFFICILE INFECTION (CDI): EVALUATION OF THE BURDEN, CURRENT PRACTICES AND SET-UP OF A EUROPEAN RESEARCH PLATFORM (PART OF THE IMI NEW DRUGS FOR BAD BUGS (ND4BB) PROGRAMME)

DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES

NEXT GENERATION OF ELECTRONIC TRANSLATIONAL SAFETY – NEXGETS

A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER

INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS

IDENTIFICATION OF DRUGGABLE TARGETS MODULATING MISFOLDED PROTEINS IN ALZHEIMER’S AND PARKINSON’S DISEASES

VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)

COORDINATION AND SUPPORT ACTIONS (CSA) FOR THE BIG DATA FOR BETTER OUTCOMES PROGRAMME

PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN

DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION

Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks